Satellos Bioscience (MSCL) AI Stock Analysis

• Market Cap: $239.15M
• Dividend Yield: N/A
• Average Volume (3M): 178.54K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.90
• Revenue Growth: N/A
• EPS Growth: 27.53%
• Country: CA
• Employees: 14
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.51
• Shares Outstanding: 15,458,929
• 10 Day Avg. Volume: 239,110
• 30 Day Avg. Volume: 178,539
• PEG Ratio: -1.22
• Price to Book (P/B): 16.85
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -45.76
• Enterprise Value/Market Cap: 0.17
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -7.38K
• Enterprise Value/Ebitda: -1.65
• 1Y Price Target: $2.14
• Price Target Upside: -86.17% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: C$15.00 ▼(-3.04% Downside)

The score is held down primarily by weak financial performance (pre-revenue, large losses, and heavy cash burn with ongoing funding risk). Technicals are supportive due to a clear uptrend, but overbought signals temper that strength. Valuation is also constrained by negative earnings and no dividend support.

Positive Factors

Low Financial Leverage

Absence of debt lowers fixed obligations and bankruptcy risk, preserving strategic optionality. For an R&D-stage biotech this durable flexibility supports continued program development, partnerships, or equity raises without debt service constraints across multiple funding cycles.

Focused Therapeutic Targeting

A specialized focus on muscle regeneration and DMD addresses a long-term unmet medical need and enables deep domain expertise. This durable niche can attract targeted partnerships, patient advocacy support, and regulatory incentives typical for rare-disease drug development.

Lean Operating Footprint

A small headcount suggests a lean organizational structure that can extend runway per dollar spent and maintain R&D focus. For an early-stage biotech, capital-efficient operations support resilience across funding cycles and facilitate nimble program prioritization.

Negative Factors

Pre-revenue Business Model

Zero revenue means the company lacks product-derived cash flow and relies on financing or collaborations to sustain operations. This structural dependency increases execution risk: long-term viability hinges on successful clinical milestones or durable external funding sources.

Persistent Cash Burn

Sustained negative operating cash flow (~ -$25M in 2024) erodes reserves and necessitates recurrent capital raises. Persistent burn reduces strategic flexibility, increases dilution risk, and pressures timelines for clinical progress and value-creating partnerships.

Eroding Equity Cushion

A meaningful drop in shareholders' equity reflects cumulative losses and/or financings that have reduced the balance sheet buffer. Lower equity heightens sensitivity to adverse outcomes, making future financing more dilutive and constraining long-term strategic options.

Satellos Bioscience Business Overview & Revenue Model

Company Description

Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system which recapitulates the muscle stem cell environment ex-vivo. Its lead program focuses on the discovery and development of a small molecule drug for the treatment of Duchenne. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

How the Company Makes Money

Satellos Bioscience generates revenue primarily through research and development partnerships, grants, and potential future licensing agreements for its proprietary technologies. The company collaborates with other biopharmaceutical firms and research institutions to advance its therapeutic candidates, receiving funding and milestone payments as these projects progress. Additionally, Satellos may pursue revenue through out-licensing its platform to other companies, allowing them to develop new treatments based on Satellos technology, which could result in royalties and license fees.

Satellos Bioscience Financial Statement Overview

Summary

Weak financial profile typical of an R&D-stage biotech: no revenue, sizable and persistent net losses, and heavy ongoing cash burn. The main offset is a low-risk capital structure with no recent debt, but declining equity and sustained negative free cash flow point to continued financing/dilution risk.

Income Statement

The company remains pre-revenue with total revenue at 0 across all periods, so profitability is entirely driven by operating spend. Losses have widened materially from 2022 to 2024 (net loss moving from about -$11.3M in 2022 to about -$28.1M in 2024), while TTM (Trailing-Twelve-Months) net loss improved modestly to about -$23.7M. Gross profit is negative throughout, consistent with an R&D-stage biotech model, but the absence of any revenue base limits visibility into operating leverage and the path to margin improvement.

Balance Sheet

The balance sheet shows no debt in recent periods (2021 through TTM (Trailing-Twelve-Months)), which reduces financial risk and adds flexibility. However, equity has declined meaningfully from about $67.9M in 2024 to about $34.0M in TTM (Trailing-Twelve-Months), suggesting ongoing losses and/or capital activity have reduced the cushion. Returns on equity are consistently negative in recent years, reflecting persistent net losses; while leverage is low, the equity trajectory highlights dilution/financing risk typical for development-stage biotech.

Cash Flow

Cash burn remains heavy and persistent: operating cash flow is negative every year, worsening from about -$14.5M in 2023 to about -$25.0M in 2024, then improving slightly to about -$24.1M in TTM (Trailing-Twelve-Months). Free cash flow closely tracks operating cash flow (also consistently negative), indicating the business is not yet self-funding. With free cash flow roughly matching net losses (around 1.0x), losses are largely translating into cash burn, reinforcing the need for continued external funding until revenues emerge.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-5.57K	-20.00K	-8.82M	-3.73M	-119.92K	-48.16K
EBITDA	-24.90M	-28.08M	-15.71M	-8.09M	-4.60M	-1.61M
Net Income	-23.68M	-28.10M	-15.89M	-11.32M	-15.51M	-1.58M
Balance Sheet
Total Assets	37.50M	73.02M	44.30M	6.20M	12.59M	1.13M
Cash, Cash Equivalents and Short-Term Investments	34.61M	69.85M	39.59M	1.92M	4.87M	717.53K
Total Debt	0.00	0.00	0.00	0.00	0.00	1.09M
Total Liabilities	3.50M	5.16M	3.62M	2.83M	2.10M	1.31M
Stockholders Equity	34.00M	67.86M	40.67M	3.37M	10.48M	-183.84K
Cash Flow
Free Cash Flow	-24.15M	-24.98M	-14.52M	-5.79M	-5.04M	-1.66M
Operating Cash Flow	-24.14M	-24.98M	-14.50M	-5.78M	-5.03M	-1.66M
Investing Cash Flow	-18.48M	6.34M	-17.54M	-3.00K	1.74M	0.00
Financing Cash Flow	55.34M	53.48M	51.03M	2.77M	7.45M	1.98M

Satellos Bioscience Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 15.47
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MSCL, the sentiment is Positive. The current price of 15.47 is above the 20-day moving average (MA) of 11.80, above the 50-day MA of 9.64, and above the 200-day MA of 8.25, indicating a bullish trend. The MACD of 1.73 indicates Negative momentum. The RSI at 72.81 is Negative, neither overbought nor oversold. The STOCH value of 76.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:MSCL.

Satellos Bioscience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HBP	52 Neutral	C$155.05M	-24.55	-66.34%	―	―	59.00%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MSCL	46 Neutral	$239.15M	-7.04	-89.10%	―	―	27.53%
MDNA	44 Neutral	C$60.48M	-5.19	-91.21%	―	―	54.74%
ARCH	43 Neutral	C$66.26M	-41.77	―	―	―	10.49%

Satellos Bioscience Corporate Events

Satellos Strengthens Executive Bench With Veteran Regulator as Duchenne Program Advances

Satellos Bioscience has appointed industry veteran Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs, bringing in a leader with a strong track record in steering breakthrough therapies such as Vertex’s cystic fibrosis drugs Kalydeco and Orkambi from clinical development to approval. The hire comes as Satellos advances two clinical studies of its lead drug SAT-3247 in adult and pediatric Duchenne muscular dystrophy patients, and is seen as a strategic move to strengthen regulatory strategy, support potential future approval pathways, and position the company for further growth as it explores broader applications of its muscle-regeneration platform.

The most recent analyst rating on (TSE:MSCL) stock is a Hold with a C$1.50 price target. To see the full list of analyst forecasts on Satellos Bioscience stock, see the TSE:MSCL Stock Forecast page.

Satellos Consolidates Shares Ahead of Proposed Nasdaq Listing

Satellos Bioscience has completed a one-for-12 consolidation of its common shares, reducing the number of outstanding shares from about 185.5 million to roughly 15.5 million, as part of its effort to meet the share price and other requirements for a proposed listing on the Nasdaq under the ticker symbol “MSLE.” Management says the consolidation is aimed at boosting the company’s market visibility, liquidity and access to a broader investor base, while maintaining shareholders’ proportional ownership and voting power, and adjusting outstanding options and pre-funded warrants accordingly, a move that could strengthen Satellos’s capital markets profile as it advances its clinical-stage muscle disease pipeline.

The most recent analyst rating on (TSE:MSCL) stock is a Hold with a C$1.00 price target. To see the full list of analyst forecasts on Satellos Bioscience stock, see the TSE:MSCL Stock Forecast page.

Satellos Bioscience to Present at December Investor Conferences

Satellos Bioscience Inc. announced its participation in two upcoming investor conferences in December, where it will present and engage in discussions on polypharmacy in DMD and neuromuscular diseases. This participation highlights Satellos’s strategic efforts to engage with investors and stakeholders, potentially impacting its industry positioning by showcasing its innovative treatments and ongoing clinical developments.

The most recent analyst rating on (TSE:MSCL) stock is a Buy with a C$1.20 price target. To see the full list of analyst forecasts on Satellos Bioscience stock, see the TSE:MSCL Stock Forecast page.

Satellos Bioscience Unveils Groundbreaking Research in Duchenne Muscular Dystrophy Treatment

Satellos Bioscience announced a significant publication in Nature Communications that supports its innovative treatment approach for Duchenne Muscular Dystrophy (DMD). The research, conducted by the Ottawa Hospital Research Institute, reveals that DMD begins as a stem cell disease during fetal development, characterized by muscle stem cell dysfunction. By targeting the AAK1 protein, Satellos’ approach aims to restore muscle regeneration, offering a potential new pathway for treating DMD. This breakthrough could redefine treatment strategies and improve outcomes for patients with DMD, highlighting the importance of addressing stem cell dysfunction in muscle diseases.

The most recent analyst rating on (TSE:MSCL) stock is a Buy with a C$1.20 price target. To see the full list of analyst forecasts on Satellos Bioscience stock, see the TSE:MSCL Stock Forecast page.

Satellos Bioscience Strengthens Leadership and Advances Clinical Trials for DMD Treatment

Satellos Bioscience announced the appointment of Mark Nawacki to its Board of Directors, leveraging his extensive experience in pharmaceuticals and corporate development to guide the company’s growth. The company has made significant strides in its clinical programs, including the submission of an IND application to the FDA for a Phase 2 trial of SAT-3247 in children with DMD, and the dosing of the first patient in a long-term study in adults. These developments are expected to enhance Satellos’ strategic positioning in the biotechnology sector and offer promising advancements for stakeholders involved in the treatment of muscular dystrophies.

The most recent analyst rating on (TSE:MSCL) stock is a Buy with a C$1.20 price target. To see the full list of analyst forecasts on Satellos Bioscience stock, see the TSE:MSCL Stock Forecast page.